Search

Sanofi SA

Fermé

SecteurSoins de santé

81.04 0.07

Résumé

Variation du prix de l'action

24h

Actuel

Min

80.98

Max

81.19

Chiffres clés

By Trading Economics

Revenu

3.9B

5.8B

Ventes

11B

21B

P/E

Moyenne du Secteur

15.922

34.393

BPA

1.59

Rendement du dividende

4.88

Marge bénéficiaire

27.234

Employés

82,878

EBITDA

2.2B

2.8B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+33.26% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

4.88%

2.54%

Prochains Résultats

24 oct. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-4.1B

100B

Ouverture précédente

80.97

Clôture précédente

81.04

Sentiment de l'Actualité

By Acuity

34%

66%

90 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Sanofi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 août 2025, 10:06 UTC

Principaux Mouvements du Marché

U.K. Bank Shares Rise After Car-Loan Ruling Softens Industry Blow -- Update

31 juil. 2025, 06:00 UTC

Résultats

Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth

30 juil. 2025, 10:20 UTC

Résultats

Santander Reports Higher Profit, but Regional Picture is Mixed -- Update

30 juil. 2025, 05:31 UTC

Résultats

Santander Sticks to Guidance, Launches $2 Billion Buyback After Profit Rises

6 août 2025, 05:02 UTC

Acquisitions, Fusions, Rachats

Sanofi Completes the Acquisition of Vigil Neuroscience

6 août 2025, 05:00 UTC

Acquisitions, Fusions, Rachats

Press Release: Sanofi Completes The Acquisition Of Vigil Neuroscience, Inc. >SAN.FR

1 août 2025, 13:16 UTC

Résultats

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 août 2025, 12:40 UTC

Résultats

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

31 juil. 2025, 08:15 UTC

Market Talk
Résultats

Sanofi's Higher Costs Take Shine off Outlook Raise -- Market Talk

31 juil. 2025, 05:56 UTC

Market Talk
Résultats

Sanofi in the Dark on Pharma Tariffs After U.S.-EU Deal -- Market Talk

31 juil. 2025, 05:30 UTC

Résultats

Sanofi 2Q Vaccine Sales Increased 10% to EUR1.2B

31 juil. 2025, 05:30 UTC

Résultats

Sanofi Says Pharma Launches Sales Increased by 40% in 2Q

31 juil. 2025, 05:30 UTC

Résultats

Sanofi 2Q Dupixent Sales Grew 21% to EUR3.8B

31 juil. 2025, 05:30 UTC

Résultats

Sanofi Intends to Complete EUR5B Buyback in 2025, With 80% Repurchased to Date

31 juil. 2025, 05:30 UTC

Résultats

Sanofi: 2025 Business EPS Guidance Now Includes Expenses From Acquisitions

31 juil. 2025, 05:30 UTC

Résultats

Sanofi 2Q Business Operating Profit EUR2.46B

31 juil. 2025, 05:30 UTC

Résultats

Sanofi 2Q Adj EPS EUR1.59

31 juil. 2025, 05:30 UTC

Résultats

Analysts Saw Sanofi 2Q Business Operating Profit at EUR2.57B

31 juil. 2025, 05:30 UTC

Résultats

Analysts Saw Sanofi 2Q Net Sales at EUR9.77B

31 juil. 2025, 05:30 UTC

Résultats

Sanofi 2Q Net Pft EUR3.94B

31 juil. 2025, 05:30 UTC

Résultats

Analysts Saw Sanofi 2Q Business EPS at EUR1.64

31 juil. 2025, 05:30 UTC

Résultats

Sanofi Now Expects 2025 Sales Growth at Constant Currency at High Single-Digit Percentage

31 juil. 2025, 05:30 UTC

Résultats

Sanofi Had Seen 2025 Sales Growth at Constant Currency at Mid-To-High Single-digit

31 juil. 2025, 05:30 UTC

Résultats

Sanofi 2Q Sales EUR9.99B

31 juil. 2025, 05:30 UTC

Résultats

Sanofi Backs 2025 EPS Adj View

31 juil. 2025, 05:30 UTC

Résultats

Sanofi Narrows 2025 Sales View

31 juil. 2025, 05:30 UTC

Résultats

Sanofi Confirms Expectations of Business EPS Rebound in 2025 Before Buybacks

30 juil. 2025, 07:48 UTC

Market Talk
Résultats

Santander Results Get Lukewarm Reaction -- Market Talk

30 juil. 2025, 06:41 UTC

Market Talk
Résultats

Santander's Strategic Investments in Focus -- Market Talk

30 juil. 2025, 04:52 UTC

Résultats

Santander End-2Q CET1 Ratio 13%

Comparaison

Variation de prix

Sanofi SA prévision

Objectif de Prix

By TipRanks

33.26% hausse

Prévisions sur 12 Mois

Moyen 107.845 EUR  33.26%

Haut 124 EUR

Bas 90 EUR

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

14 ratings

10

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

91.3 / 96.1Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

90 / 374Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.